(BAYN) Bayer NA - XETRA
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: XETRA (Germany) | Market Cap: 37.175m EUR | Total Return: 46% in 12m
Avg Turnover: 107M
EPS Trend: -82.7%
Qual. Beats: 1
Rev. Trend: -97.6%
Qual. Beats: 0
Warnings
High Debt/EBITDA (9.6) with thin interest coverage (0.2)
Interest Coverage Ratio 0.2 is critical
Altman Z'' 0.74 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Bayer AG is a German life sciences company operating through three primary divisions: Pharmaceuticals, Crop Science, and Consumer Health. The Pharmaceuticals segment focuses on prescription therapeutics for cardiology, oncology, and women’s health, while the Consumer Health division manages over-the-counter brands in dermatology and nutrition. The Crop Science segment provides seeds, digital farming tools, and chemical crop protection solutions to the global agricultural market.
The company operates within the highly regulated life sciences sector, where business models are heavily dependent on research and development (R&D) cycles and patent protections. Bayer utilizes a diversified distribution network ranging from direct sales to farmers and hospitals to retail partnerships through pharmacies and supermarkets.
Reviewing the historical performance metrics on ValueRay can provide further clarity on the companys valuation.
- Glyphosate litigation settlement costs and legal liabilities weigh on corporate valuation
- Declining crop science margins reflect falling herbicide pricing and high inventory
- Pharmaceutical pipeline success for Kerendia and Nubeqa offsets patent expirations
- High debt levels from Monsanto acquisition limit capital allocation and dividends
- Regulatory shifts in agricultural biotechnology impact market access for genetically modified seeds
| Net Income: -2.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.97 > 1.0 |
| NWC/Revenue: 4.07% < 20% (prev 14.76%; Δ -10.69% < -1%) |
| CFO/TA 0.04 > 3% & CFO 4.52b > Net Income -2.16b |
| Net Debt (33.5b) to EBITDA (3.51b): 9.56 < 3 |
| Current Ratio: 1.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (982.4m) vs 12m ago 0.0% < -2% |
| Gross Margin: 59.32% > 18% (prev 53.99%; Δ 5.33% > 0.5%) |
| Asset Turnover: 41.67% > 50% (prev 42.66%; Δ -0.99% > 0%) |
| Interest Coverage Ratio: 0.25 > 6 (EBIT TTM 641.0m / Interest Expense TTM 2.61b) |
| A: 0.02 (Total Current Assets 35.3b - Total Current Liabilities 33.5b) / Total Assets 108b |
| B: 0.06 (Retained Earnings 6.73b / Total Assets 108b) |
| C: 0.01 (EBIT TTM 641.0m / Avg Total Assets 109b) |
| D: 0.37 (Book Value of Equity 28.8b / Total Liabilities 79.0b) |
| Altman-Z'' = 0.74 = B |
| DSRI: 1.02 (Receivables 16.6b/16.7b, Revenue 45.2b/46.6b) |
| GMI: 0.91 (GM 53.99% / 59.32%) |
| AQI: 0.99 (AQ_t 0.56 / AQ_t-1 0.56) |
| SGI: 0.97 (Revenue 45.2b / 46.6b) |
| TATA: -0.06 (NI -2.16b - CFO 4.52b) / TA 108b) |
| Beneish M = -3.12 (Cap -4..+1) = AA |
As of June 23, 2026, the stock is trading at EUR 38.18 with a total of 3,357,951 shares traded. Over the past week, the price has changed by +5.15%, over one month by -0.86%, over three months by -0.46% and over the past year by +45.95%.
Current recommended Stop Loss: 35.70 (which is 6.5% or 2 ATR below the current price).
Bayer NA has no consensus analysts rating.
P/E Forward = 8.5179
P/S = 0.8217
P/B = 1.2653
P/EG = 4.7193
Revenue TTM = 45.2b EUR
EBIT TTM = 641.0m EUR
EBITDA TTM = 3.51b EUR
Long Term Debt = 30.8b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 8.20b EUR (from shortTermDebt, last quarter)
Debt = 40.2b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.29b
Net Debt = 33.5b EUR (calculated: Debt 40.2b - CCE 6.66b)
Enterprise Value = 70.7b EUR (37.2b + Debt 40.2b - CCE 6.66b)
Interest Coverage Ratio = 0.25 (Ebit TTM 641.0m / Interest Expense TTM 2.61b)
EV/FCF = 35.12x (Enterprise Value 70.7b / FCF TTM 2.01b)
FCF Yield = 2.85% (FCF TTM 2.01b / Enterprise Value 70.7b)
FCF Margin = 4.45% (FCF TTM 2.01b / Revenue TTM 45.2b)
Net Margin = -4.77% (Net Income TTM -2.16b / Revenue TTM 45.2b)
Gross Margin = 59.32% ((Revenue TTM 45.2b - Cost of Revenue TTM 18.4b) / Revenue TTM)
Gross Margin QoQ = 60.97% (prev 60.65%)
Tobins Q-Ratio = 0.65 (Enterprise Value 70.7b / Total Assets 108b)
Interest Expense / Debt = 6.50% (Interest Expense 2.61b / Debt 40.2b)
Taxrate = 7.43% (222.0m / 2.99b)
NOPAT = 593.4m (EBIT 641.0m * (1 - 7.43%))
Current Ratio = 1.06 (Total Current Assets 35.3b / Total Current Liabilities 33.5b)
Debt / Equity = 1.39 (Debt 40.2b / totalStockholderEquity, last quarter 28.8b)
Debt / EBITDA = 9.56 (Net Debt 33.5b / EBITDA 3.51b)
Debt / FCF = 16.65 (Net Debt 33.5b / FCF TTM 2.01b)
Total Stockholder Equity = 28.7b (last 4 quarters mean from totalStockholderEquity)
RoA = -1.99% (Net Income -2.16b / Total Assets 108b)
RoE = -7.52% (Net Income TTM -2.16b / Total Stockholder Equity 28.7b)
RoCE = 1.08% (EBIT 641.0m / Capital Employed (Equity 28.7b + L.T.Debt 30.8b))
RoIC = 0.74% (NOPAT 593.4m / Invested Capital 80.4b)
WACC = 6.77% (E(37.2b)/V(77.3b) * Re(7.58%) + D(40.2b)/V(77.3b) * Rd(6.50%) * (1-Tc(0.07)))
Discount Rate = 7.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -9.76 | Cagr: -0.00%
[DCF] Terminal Value 73.10% ; FCFF base≈3.32b ; Y1≈2.91b ; Y5≈2.35b
[DCF] Fair Price = 4.29 (EV 37.7b - Net Debt 33.5b = Equity 4.21b / Shares 982.4m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -82.65 | EPS CAGR: -10.01% | SUE: 2.64 | # QB: 1
Revenue Correlation: -97.63 | Revenue CAGR: -2.25% | SUE: -0.48 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.87 | Chg30d=N/A | Revisions=+0% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.60 | Chg30d=N/A | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=4.40 | Chg30d=+1.84% | Revisions=+56% | GrowthEPS=-10.4% | GrowthRev=-0.1%
EPS next Year (2027-12-31): EPS=4.72 | Chg30d=-0.28% | Revisions=-18% | GrowthEPS=+7.3% | GrowthRev=+2.8%
[Analyst] Revisions Ratio: +56%